ADRO Aduro Biotech Inc.

2.74
+0.01  (+0%)
Previous Close 2.73
Open 2.72
Price To Book 1.38
Market Cap 217567190
Shares 79,404,084
Volume 413,807
Short Ratio
Av. Daily Volume 751,650

SEC filingsSee all SEC filings

  1. 8-K - Current report 181171381
  2. 8-K - Current report 181147120
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181147079
  4. 8-K - Current report 181097466
  5. 8-K - Current report 181068945

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation announced December 18, 2017.
BION-1301
Multiple Myeloma
Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
ADU-S100
Solid tumors or lymphomas
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Noted December 12, 2017 that development to be discontinued.
CRS-207 with pembrolizumab
Mesothelioma - cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1b initiation announced June 7, 2018.
ADU-214 with Nivolumab
Non-Small Cell Lung Cancer

Latest News

  1. Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity
  2. Aduro Biotech Enters Oversold Territory
  3. Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition
  4. Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas
  5. Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
  6. New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A — Factors of Influence, Major Initiatives and Sustained Production
  7. Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
  8. Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates
  9. Aduro Biotech Reports Third Quarter 2018 Financial Results
  10. Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018
  11. Aduro Biotech (ADRO) Q3 Earnings Preview: What's in the Cards?
  12. Why Aduro Biotech Crashed 29.5% Today
  13. Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
  14. Aduro Biotech to Present at Two Investor Conferences in October
  15. Aduro Biotech Announces the Departure of Natalie R. Sacks, M.D.
  16. Implied Volatility Surging for Aduro BioTech (ADRO) Stock Options
  17. Are Insiders Cautious About Aduro BioTech Inc (NASDAQ:ADRO) Shares?
  18. Aduro Biotech (ADRO) Up 17.4% Since Last Earnings Report: Can It Continue?

SEC Filings

  1. 8-K - Current report 181171381
  2. 8-K - Current report 181147120
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181147079
  4. 8-K - Current report 181097466
  5. 8-K - Current report 181068945
  6. 8-K - Current report 18985046
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18984887
  8. 8-K - Current report 18890405
  9. 8-K - Current report 18800179
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18800041